Anti-cancer Immunotherapies Targeting Telomerase.
cancer
clinical trials
hTERT
immunotherapy
telomerase
vaccine
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
12 Aug 2020
12 Aug 2020
Historique:
received:
13
07
2020
revised:
05
08
2020
accepted:
07
08
2020
entrez:
19
8
2020
pubmed:
19
8
2020
medline:
19
8
2020
Statut:
epublish
Résumé
Telomerase is a reverse transcriptase that maintains telomeres length, compensating for the attrition of chromosomal ends that occurs during each replication cycle. Telomerase is expressed in germ cells and stem cells, whereas it is virtually undetectable in adult somatic cells. On the other hand, telomerase is broadly expressed in the majority of human tumors playing a crucial role in the replicative behavior and immortality of cancer cells. Several studies have demonstrated that telomerase-derived peptides are able to bind to HLA (human leukocyte antigen) class I and class II molecules and effectively activate both CD8
Identifiants
pubmed: 32806719
pii: cancers12082260
doi: 10.3390/cancers12082260
pmc: PMC7465444
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cold Spring Harb Perspect Biol. 2013 May 01;5(5):a010405
pubmed: 23543032
Br J Cancer. 2006 Dec 4;95(11):1474-82
pubmed: 17060934
Genome Med. 2016 Jun 20;8(1):69
pubmed: 27323951
Front Immunol. 2019 Jan 21;9:3176
pubmed: 30719026
Urology. 2018 Mar;113:129-137
pubmed: 29154986
Cancer Immunol Immunother. 2006 Dec;55(12):1553-64
pubmed: 16491401
Hum Vaccin Immunother. 2017 Aug 3;13(8):1774-1777
pubmed: 28604160
Oncoimmunology. 2019 Jan 19;8(4):e1565236
pubmed: 30906659
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Curr Top Med Chem. 2016;16(22):2432-40
pubmed: 26873194
J Immunol Methods. 2002 Jan 1;259(1-2):191-203
pubmed: 11730854
J Clin Invest. 2015 Sep;125(9):3356-64
pubmed: 26168215
Hum Immunol. 2012 Mar;73(3):207-13
pubmed: 22285846
Cancer Immunol Immunother. 2012 Oct;61(10):1791-804
pubmed: 22426890
J Transl Med. 2009 Mar 19;7:18
pubmed: 19298672
Cancer Res. 2016 May 1;76(9):2540-51
pubmed: 27197263
Curr Top Med Chem. 2020;20(6):433-457
pubmed: 31894749
Nat Rev Clin Oncol. 2017 Feb;14(2):115-128
pubmed: 27245281
Br J Dermatol. 2007 Dec;157 Suppl 2:8-13
pubmed: 18067624
Cancer Immunol Immunother. 2011 Nov;60(11):1553-64
pubmed: 21681371
BMC Cancer. 2010 May 17;10:209
pubmed: 20478057
Gene Ther. 2007 Apr;14(8):657-63
pubmed: 17287861
Science. 1994 Dec 23;266(5193):2011-5
pubmed: 7605428
Hum Vaccin Immunother. 2013 Dec;9(12):2543-7
pubmed: 23978951
Int J Oncol. 2014 Sep;45(3):1293-303
pubmed: 24919654
Blood. 2001 May 1;97(9):2903-7
pubmed: 11313288
Sci Rep. 2015 Jun 18;5:11275
pubmed: 26085010
Case Rep Med. 2016;2016:9639585
pubmed: 27504122
Blood. 2006 Feb 15;107(4):1505-12
pubmed: 16249379
J Immunother. 2011 Nov-Dec;34(9):641-50
pubmed: 21989412
Mol Ther Methods Clin Dev. 2014 Sep 24;1:14045
pubmed: 26015983
Cancer Gene Ther. 2003 Mar;10(3):239-49
pubmed: 12637945
Ann Oncol. 2012 Feb;23(2):442-9
pubmed: 21873272
Nature. 1999 Jul 29;400(6743):464-8
pubmed: 10440377
J Immunother Cancer. 2016 Sep 20;4:56
pubmed: 27660710
Blood. 2013 Jun 13;121(24):4894-901
pubmed: 23641014
Int J Oncol. 2015 Nov;47(5):1901-11
pubmed: 26398907
Lung Cancer. 2014 Oct;86(1):59-66
pubmed: 25130084
Oncotarget. 2016 Nov 15;7(46):75081-75093
pubmed: 27655706
Nat Med. 1999 Oct;5(10):1164-70
pubmed: 10502820
Cancer Immunol Immunother. 2012 Feb;61(2):157-168
pubmed: 21858533
J Immunol. 2005 Jun 15;174(12):8210-8
pubmed: 15944330
Nat Med. 2000 Sep;6(9):1011-7
pubmed: 10973321
Cancer Immunol Immunother. 2011 Jun;60(6):809-18
pubmed: 21365467
Hum Vaccin Immunother. 2015;11(4):838-50
pubmed: 25714118
Cancer Lett. 2015 Aug 10;364(2):98-105
pubmed: 25982205
Cancer Res. 2007 Nov 1;67(21):10546-55
pubmed: 17974999
Oncotarget. 2016 Sep 20;7(38):60872-60884
pubmed: 27563821
Cancer Immunol Immunother. 2013 May;62(5):851-62
pubmed: 23359087
Cancer Res. 2005 Jun 15;65(12):5417-27
pubmed: 15958591
FEBS Lett. 2018 Jun;592(12):2023-2031
pubmed: 29749098
Blood. 2011 Jan 20;117(3):788-97
pubmed: 21030558
Hum Immunol. 2013 Feb;74(2):166-9
pubmed: 23200754
Curr Oncol. 2020 Apr;27(Suppl 2):S87-S97
pubmed: 32368178
Cancer. 2017 Aug 15;123(16):3061-3072
pubmed: 28411378
J Immunol. 2002 Jun 1;168(11):5900-6
pubmed: 12023395
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5147-52
pubmed: 10220433
Oncoimmunology. 2012 Aug 1;1(5):670-686
pubmed: 22934259
Expert Rev Vaccines. 2002 Jun;1(1):111-8
pubmed: 12908518
Cancer Immunol Immunother. 2017 Jul;66(7):891-901
pubmed: 28391357
Vaccine. 2006 Mar 10;24(11):1958-65
pubmed: 16310898
Chromosoma. 2016 Jun;125(2):337-51
pubmed: 26525972
Exp Hematol. 2005 Nov;33(11):1275-80
pubmed: 16263411
Cancer Res. 2002 Sep 1;62(17):5041-8
pubmed: 12208759
Clin Cancer Res. 2011 Jul 1;17(13):4568-80
pubmed: 21586625
Oncoimmunology. 2015 Nov 5;5(3):e1083670
pubmed: 27141336
J Clin Oncol. 2007 Jul 1;25(19):2727-34
pubmed: 17602077
Oncology. 2006;70(4):306-14
pubmed: 17047402
J Immunother. 2008 Oct;31(8):771-80
pubmed: 18779742
Mol Biol Rep. 2019 Feb;46(1):1401-1411
pubmed: 30448892
J Hematol Oncol. 2017 Apr 7;10(1):82
pubmed: 28388966
J Dermatol Sci. 2011 May;62(2):75-83
pubmed: 21377838
Semin Immunol. 2018 Oct;39:119-136
pubmed: 29709421
J Clin Invest. 2004 Feb;113(3):425-33
pubmed: 14755339
Oncol Rep. 2012 Dec;28(6):1945-52
pubmed: 22992764
Clin Cancer Res. 2011 Nov 1;17(21):6847-57
pubmed: 21918169
Clin Cancer Res. 2004 Jul 15;10(14):4688-98
pubmed: 15269141
Blood. 2010 Mar 4;115(9):1678-89
pubmed: 19903895
Biomaterials. 2014 Mar;35(9):2924-33
pubmed: 24411674
Clin Cancer Res. 2020 Feb 1;26(3):588-597
pubmed: 31558479
Cancers (Basel). 2020 Apr 11;12(4):
pubmed: 32290440
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12275-80
pubmed: 12218171
Cytotherapy. 2010 Oct;12(6):721-34
pubmed: 20429791
Nat Rev Mol Cell Biol. 2020 Jul;21(7):384-397
pubmed: 32242127
Mol Cell Biol. 1996 Jan;16(1):53-65
pubmed: 8524329
Clin Cancer Res. 2003 Oct 15;9(13):4743-55
pubmed: 14581345
Genes Dev. 1999 Sep 15;13(18):2388-99
pubmed: 10500096
Clin Cancer Res. 2001 Nov;7(11):3343-8
pubmed: 11705846
Cancer Immunol Res. 2013 Sep;1(3):179-189
pubmed: 24777680
J Immunol. 2005 Mar 15;174(6):3798-807
pubmed: 15749921
Front Immunol. 2019 Jun 06;10:925
pubmed: 31244820
Int Immunol. 2006 Dec;18(12):1707-18
pubmed: 17077179
Oncol Rep. 2004 Oct;12(4):871-6
pubmed: 15375515
Clin Cancer Res. 2004 Feb 1;10(3):828-39
pubmed: 14871958
Immunity. 1999 Jun;10(6):673-9
pubmed: 10403642
Cancer Immunol Immunother. 2013 Sep;62(9):1499-509
pubmed: 23817721
Immunotherapy. 2017 Mar;9(4):347-360
pubmed: 28303764
Acta Oncol. 2017 Apr;56(4):503-515
pubmed: 28358664
Oncotarget. 2016 Sep 13;7(37):59417-59428
pubmed: 27506946
Gene. 2018 Jan 30;641:235-239
pubmed: 29074462
Clin Cancer Res. 2012 May 15;18(10):2943-53
pubmed: 22407833
Ann N Y Acad Sci. 2006 Jun;1069:377-85
pubmed: 16855164
Protein Cell. 2020 Aug;11(8):549-564
pubmed: 32221812
Ann Transl Med. 2016 Jul;4(14):266
pubmed: 27563653
Cells. 2020 Mar 19;9(3):
pubmed: 32204305
Br J Cancer. 2020 May;122(10):1461-1466
pubmed: 32210365
Oncoimmunology. 2016 Oct 24;5(12):e1249090
pubmed: 28123886
Cell Mol Life Sci. 2017 Nov;74(22):4121-4132
pubmed: 28623509
Science. 2009 Nov 13;326(5955):948-52
pubmed: 19965504
Int J Mol Sci. 2016 Dec 07;17(12):
pubmed: 27941629
Cancer Immunol Immunother. 2013 Jun;62(6):1041-52
pubmed: 23591981
Cancer Res. 2002 May 1;62(9):2600-5
pubmed: 11980655
J Transl Med. 2007 Feb 26;5:12
pubmed: 17324292
J Immunol Methods. 2019 Mar;466:1-8
pubmed: 30468736
Lancet Oncol. 2014 Jul;15(8):829-40
pubmed: 24954781
Br J Cancer. 2007 Apr 10;96(7):1020-4
pubmed: 17353922
Antioxidants (Basel). 2017 Feb 19;6(1):
pubmed: 28218725
J Clin Oncol. 2000 Jul;18(13):2626-34
pubmed: 10893296
Trends Biochem Sci. 2013 Sep;38(9):426-34
pubmed: 23932019
Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4796-801
pubmed: 10759561